Get started
Author

Adela Rodríguez Hernandez

Genotype matters: Personalized screening recommendations for germline CHEK2 variants
2024 · Adela Rodriguez Hernandez, Rochelle Scheib, et al. · Oncotarget · 6
CHEK2-related breast cancer: real-world challenges
2025 · Luiza N. Weis, Brittany L. Bychkovsky, et al. · Familial Cancer · 4
Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
2026 · Benedetta Conte, Fara Brasó-Maristany, et al. · Clinical Cancer Research · 1
AXALAP: Phase Ib study of axatilimab in combination with olaparib in BRCA1/2 and PALB2 -associated metastatic HER2-negative breast cancer (BC).
2025 · Filipa Lynce, Adela Rodriguez Hernandez, et al. · Journal of Clinical Oncology · 1
PDF
Actionable germline findings in endometrial cancer from a large multigene panel tested cohort.
2026 · Adela Rodriguez Hernandez, Magan Trottier, et al. · Journal of Clinical Oncology
Abstract PD4-10: The prognosis of invasive early hormone receptor positive HER2 negative breast cancer in women harboring a pathogenic or likely pathogenic TP53 germline variant
2026 · R. Sandoval, L. Tianyu, et al. · Clinical Cancer Research
Abstract PS2-02-07: Impact of BRCA homozygous copy loss on clinical outcomes of patients (pts) with metastatic breast cancer (MBC) treated with PARP inhibitors (PARPi)
2026 · A. Rodríguez-Hernández, J. Quintanilla, et al. · Clinical Cancer Research
Abstract P2-05-18: Molecular effects of short pre-operative endocrine therapy in hormone receptor-positive and HER2-negative early breast cancer
2025 · Raquel Gómez-Bravo, Barbara Adamo, et al. · Clinical Cancer Research
Abstract 2262: A case-control analysis of germline pathogenic variants among patients with sarcoma
2025 · Adela Rodriguez Hernandez, Miki Horiguchi, et al. · Cancer Research
Works count: 9
Citation count: 12
H-index: 2
I10-index:
Year
Topic
Type